Stockreport

Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet [Seeking Alpha]

Lyell Immunopharma, Inc.  (LYEL) 
PDF Ronde-cel's 93% ORR, 76% CR, and ~18-month mPFS in 3L+ LBCL patients outperformed approved peers, supporting a $1B+ peak sales opportunity. Valuation estimates sugges [Read more]